Seagen, Inc. (SGEN)
| Market Cap | 28.80B |
| Revenue (ttm) | 2.27B |
| Net Income (ttm) | 660.65M |
| Shares Out | 181.48M |
| EPS (ttm) | 3.58 |
| PE Ratio | 43.95 |
| Forward PE | 909.09 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $157.50 |
| Previous Close | $156.88 |
| Change ($) | 0.62 |
| Change (%) | 0.40% |
| Day's Open | 158.25 |
| Day's Range | 157.22 - 160.48 |
| Day's Volume | 251,183 |
| 52-Week Range | 133.20 - 213.94 |
BOTHELL, Wash.--(BUSINESS WIRE)-- #ASCO2021--Seagen Announces Long-Term Results from Pivotal Trial in Patients with HER2-Positive Breast Cancer During the 2021 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday...
TOKYO and BOTHELL, Wash., May 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)-- #ASCO21--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results fr...
Their revenue prospects are the ticket to future share price performance.
Although they have been struggling recently, these stocks remain attractive buys over the long term.
Final Trades: Uber, ViacomCBS, Moderna & more
The "Halftime Report" traders give their top picks to watch for the second half.
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.56% and -2.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Seagen (NASDAQ:SGEN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 31.63% over the past year to ($0.67), which missed th...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the first quarter and three months ended March 31, 2021. The Company also highlighted ADCETRIS® (brentuxim...
BOTHELL, Wash.--(BUSINESS WIRE)-- #ASCO2021--Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
Seattle Genetics (NASDAQ:SGEN) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings announcement.
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.
TOKYO and BOTHELL, Wash., April 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that preclinical data from its pipeline of novel targeted oncology drugs will be presented at the American Association for Can...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2021 financial results on Thursday, April 29, 2021 after the close of U.S. financial mar...
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
TOKYO and BOTHELL, Wash., March 26, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorizati...
Seagen (SGEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
The price is right for these stocks, which are promising big revenue.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that it has been notified of an unsolicited “mini-tender” offer dated February 22, 2021, made by TRC Capital Investment Corpora...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at...
Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.
TOKYO and BOTHELL, Wash., Feb. 18, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced completion of...
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of submissions fo...
The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced primary results from the pha...
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the second coho...
Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that the European Commission (EC) has granted marketing authorization for TUKYSA® (tucatinib) in combination with trastuzumab a...
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2020. The Company also highlighted ADCETRIS® (brentuximab v...
Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food a...
Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The rumor mill took hold in late-day trading.
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...
Revenue growth is just beginning for these companies.
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2020 financial results on Thursday, February 11, 2021 after the close of ...
Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% year...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 2:00 ...
About SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. I... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol SGEN |
Analyst Forecasts
According to 19 analysts, the average rating for Seagen stock is "Buy." The 12-month stock price forecast is 189.13, which is an increase of 20.08% from the latest price.